Orgenesis, Inc.

As of February 9, 2024, Orgenesis, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics and a 1-year return of -71.41%, significantly underperforming its peers and the S&P 500.

As of June 13, 2025, the technical trend has shifted to a moderate bearish stance, supported by bearish indicators such as MACD, Bollinger Bands, moving averages, KST, and OBV, along with significant underperformance compared to the S&P 500.

As of March 2022, the management team of Orgenesis, Inc. is led by Ms. Vered Caplan as Chairperson and CEO, alongside independent directors Mr. Yaron Adler, Mr. Ashish Nanda, Mr. Mario Philips, Dr. David Sidransky, and Mr. Guy Yachin.

Orgenesis, Inc. is a biopharmaceutical company specializing in cell and gene therapy technologies and services. As of September 2024, it reported net sales of $0 million and a net loss of $9 million, with a market cap of $9.98 million.

As of Jun 18, Orgenesis, Inc. has a market capitalization of 9.98 million, with net sales of 0.91 million and a net profit of -35.27 million over the last four quarters. The company reported shareholder's funds of -20.98 million and total assets of 14.55 million as of Dec 23.